Lumida
/ESPR
⌘K
Esperion Therapeutics Inc

Esperion Therapeutics Inc

ESPR
$3.18USD-0.31%-0.01 today

MARKET CAP

819.5M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$1
$4

AI Summary

Stalk
Buy NowMedium

We remain bullish across all horizons as ESPR sits in a Stage 2 advance with a fresh higher-high/higher-low structure driven by a Lockout Rally above rising EMAs. The active Lockout Rally override validates a Buy Now posture despite near-term extension, favoring participation on shallow retracements into the 9/20 EMA support zone. Moderate distribution risk exists as EMAs flatten near recent highs, warranting vigilance for a shift in momentum.

  • Merger with Essence MergerCo enhances scale, capital, and efficiency.
  • 30% of patients cannot tolerate statins, creating a large addressable market.
  • Trading suspended for the merger poses liquidity risk and uncertainty.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$78.4M$75.5M$116.3M$332.3M$403.1M
YoY %-65.5%-3.8%+54.1%+185.7%+21.3%
P / Sales1.8x5.1x2.6x1.2x1.9x
EV / Sales6.6x11.1x7.6x3.0x3.4x
Gross Profit, Adj.$78.4M$75.5M$116.3M$332.3M$403.1M
YoY %-65.5%-3.8%+54.1%+185.7%+21.3%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit6.6x11.1x7.6x3.0x3.4x
EBITDA, Adj.$-226.1M$-179.0M$-155.4M$54.5M$60.4M
YoY %-87.1%+20.8%+13.2%+135.0%+10.9%
Margin %-288.2%-237.2%-133.6%16.4%15.0%
EV / EBITDA-2.3x-4.7x-5.7x18.4x22.7x
EBIT$-226.7M$-179.5M$-155.6M$54.4M$60.3M
YoY %-86.8%+20.8%+13.3%+135.0%+10.8%
Margin %-289.0%-237.8%-133.7%16.4%15.0%
EV / EBIT-2.3x-4.7x-5.7x18.4x22.7x
Net Income$-269.1M$-233.7M$-209.2M$-51.7M$-22.7M
YoY %-87.5%+13.2%+10.4%+75.3%+56.2%
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (GAAP)-$9.31-$3.52-$2.03-$0.28-$0.11
YoY %-78.0%+62.2%+42.3%+86.2%+60.7%